Article info
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
517 Splenic tumor-reactive CD8+ T cells are endowed with a unique potential for expansion and are the dominant source of systemic anti-tumor immunity after ICB therapy
Citation
517 Splenic tumor-reactive CD8+ T cells are endowed with a unique potential for expansion and are the dominant source of systemic anti-tumor immunity after ICB therapy
Publication history
- First published November 7, 2022.
Online issue publication
April 26, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.